RT Journal Article
T1 Intravenous supplementation type and volume are associated with 1-year outcome and major complications in patients with chronic intestinal failure.
A1 Pironi, Loris
A1 Steiger, Ezra
A1 Joly, Francisca
A1 Wanten, Geert J A
A1 Chambrier, Cecile
A1 Aimasso, Umberto
A1 Sasdelli, Anna Simona
A1 Szczepanek, Kinga
A1 Jukes, Amelia
A1 Theilla, Miriam
A1 Kunecki, Marek
A1 Daniels, Joanne
A1 Serlie, Mireille J
A1 Cooper, Sheldon C
A1 Poullenot, Florian
A1 Rasmussen, Henrik Højgaard
A1 Compher, Charlene W
A1 Crivelli, Adriana
A1 Hughes, Sarah-Jane
A1 Santarpia, Lidia
A1 Guglielmi, Francesco William
A1 Rotovnik Kozjek, Nada
A1 Ellegard, Lars
A1 Schneider, Stephane M
A1 Matras, Przemysław
A1 Forbes, Alastair
A1 Wyer, Nicola
A1 Zmarzly, Anna
A1 Taus, Marina
A1 O'Callaghan, Margie
A1 Osland, Emma
A1 Thibault, Ronan
A1 Cuerda, Cristina
A1 Jones, Lynn
A1 Chapman, Brooke
A1 Sahin, Peter
A1 Virgili, Nuria M
A1 Lee, Andre Dong Won
A1 Orlandoni, Paolo
A1 Matysiak, Konrad
A1 Di Caro, Simona
A1 Doitchinova-Simeonova, Maryana
A1 Masconale, Luisa
A1 Spaggiari, Corrado
A1 Garde, Carmen
A1 Serralde-Zuñiga, Aurora E
A1 Olveira, Gabriel
A1 Krznaric, Zeljko
A1 Petrina Jauregui, Estrella
A1 Zugasti Murillo, Ana
A1 Suarez-Llanos, Jose P
A1 Nardi, Elena
A1 Van Gossum, Andre
A1 Lal, Simon
K1 Intestinal failure
K1 Liver failure
K1 Motility disorders
K1 Parenteral nutrition
K1 Short bowel syndrome
AB No marker to categorise the severity of chronic intestinal failure (CIF) has been developed. A 1-year international survey was carried out to investigate whether the European Society for Clinical Nutrition and Metabolism clinical classification of CIF, based on the type and volume of the intravenous supplementation (IVS), could be an indicator of CIF severity. At baseline, participating home parenteral nutrition (HPN) centres enrolled all adults with ongoing CIF due to non-malignant disease; demographic data, body mass index, CIF mechanism, underlying disease, HPN duration and IVS category were recorded for each patient. The type of IVS was classified as fluid and electrolyte alone (FE) or parenteral nutrition admixture (PN). The mean daily IVS volume, calculated on a weekly basis, was categorised as 3 L/day. The severity of CIF was determined by patient outcome (still on HPN, weaned from HPN, deceased) and the occurrence of major HPN/CIF-related complications: intestinal failure-associated liver disease (IFALD), catheter-related venous thrombosis and catheter-related bloodstream infection (CRBSI). Fifty-one HPN centres included 2194 patients. The analysis showed that both IVS type and volume were independently associated with the odds of weaning from HPN (significantly higher for PN 1 L/day), patients' death (lower for FE, p=0.079), presence of IFALD cholestasis/liver failure and occurrence of CRBSI (significantly higher for PN 2-3 and PN >3 L/day). The type and volume of IVS required by patients with CIF could be indicators to categorise the severity of CIF in both clinical practice and research protocols.
PB BMJ Group
SN 0017-5749
YR 2020
FD 2020-01-21
LK http://hdl.handle.net/10668/14982
UL http://hdl.handle.net/10668/14982
LA en
NO Pironi L, Steiger E, Joly F, Wanten GJA, Chambrier C, Aimasso U, et al. Intravenous supplementation type and volume are associated with 1-year outcome and major complications in patients with chronic intestinal failure. Gut. 2020 Oct;69(10):1787-1795
DS RISalud
RD Aug 18, 2025